Abstracts tagged "Clinical"

Abstract Number: 2404 • 2014 ACR/ARHP Annual Meeting
RA Patients with Inadequate Response to Oral MTX Maintain Satisfactory Disease Control and Durable Long-Term Response When Switched to SC MTX Monotherapy
Anthony Hammond¹ and Michael Batley², ¹Rheumatology, Maidstone and Tunbridge Wells NHS Trust, Kent TN13 2JD, United Kingdom, ²Rheumatology, Maidstone and Tunbridge Wells Hospital, Kent, United Kingdom
Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) therapy, but many patients do not achieve adequate response to oral therapy for reasons of…
Abstract Number: 1420 • 2014 ACR/ARHP Annual Meeting
Non-Use of Glucocorticoid and Osteoarthritis Absence As Predictors of Clinical Remission in AR
Salvador Loredo-Alanís¹, David Vega-Morales², Mario Garza-Elizondo¹, Mario Garcia-Pompermayer³, Roberto Negrete-López¹, Daniel Treviño-Montes¹ and Diana Flores-Alvarado², ¹Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Rheumatology, Hospital Universitario UANL, Monterrey, Mexico, ³Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterey, Mexico
Background/Purpose The clinical evaluation of Rheumatoid arthritis (RA) is accomplished with compound indexes allowing better clinical decision. Clinical remission nowadays is an attainable target in…
Abstract Number: 1318 • 2014 ACR/ARHP Annual Meeting
Illness Onset Features and Misdiagnosis in Juvenile Idiopathic Inflammatory Myopathies (JIIM) Differ Among Clinical and Autoantibody (Ab) Subgroups
Gulnara Mamyrova¹, Lan Wu², Adam Huber³, Ira N. Targoff⁴, Frederick W. Miller² and Lisa G. Rider², ¹Rheumatology, George Washington University, Washington, DC, ²Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ³IWK Health Centre, Halifax, NS, Canada, ⁴Veterans Affairs Medical Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: To evaluate features of JIIM clinical and Ab subgroups at illness onset. Methods: Physician-completed questionnaires illness onset features were reviewed in 465 JIIM pts…
Abstract Number: 1193 • 2014 ACR/ARHP Annual Meeting
Diagnostic value of Contrast-Enhanced MR-Angiography in diagnosing large Vessel Vasculitis
Sabine Adler¹, Marco Sprecher¹, Harald Bonel², Thorsten Klink² and Peter M. Villiger³, ¹Rheumatology, Immunology, Allergology, University Hospital Bern, Bern, Switzerland, ²Diagnostic, Interventional and Pediatric Radiology, University Hospital Bern, Bern, Switzerland, ³Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland
Background/Purpose Diagnosis of large-vessel vasculitis (LVV) remains difficult despite clinical and serological signs and symptoms. Detection by histology might be unavailable in exclusive thoracic or…
Abstract Number: 125 • 2013 ACR/ARHP Annual Meeting
Correlation Of Findings In Clinical and High Resolution Ultrasonography Examinations Of The Painful Shoulder
Raphael Micheroli¹, Diego Kyburz², Adrian Ciurea³, Beat Dubs⁴, Martin Toniolo², Samuel Bisig⁵ and Giorgio Tamborrini⁶, ¹Faculty of Medicine, University of Zurich, Zurich, Switzerland, ²Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, ³Center of Experimental Rheumatology, University Hospital Zurich, Zurich Schlieren, Switzerland, ⁴Sonography Institute Bethanien Zurich, Zurich, Switzerland, ⁵Swiss Federal Institute of Technology Zurich, Zurich, Switzerland, ⁶Department of Rheumatology and Musculoskeletal Ultrasound, Bethesda Hospital Basel, Basel, Switzerland
Background/Purpose: High resolution ultrasonography (HRUS) is a non-painful and non-invasive imaging technique which is increasingly used for evaluating patients with musculoskeletal disorders. In particular, HRUS…
Abstract Number: 2527 • 2013 ACR/ARHP Annual Meeting
Association Of Nail Dystrophy With Capillaroscopic Abnormalities, Anti-Endothelial Cell Antibody, Endothelin-1, Activity and Chronicity In Systemic Lupus Erythematosus
Violeta Higuera¹, Luis M. Amezcua-Guerra², Felipe Massó³, Mariana Patlan⁴, Hugo Montoya⁵, Araceli Paez⁴ and Luis H. Silveira⁶, ¹Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, ²Rheumatology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, ³Immunology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, ⁴Immunology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, ⁵Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, ⁶Rheumatology, Instituto Nacional Cardiología Ignacio Chávez, Mexico City, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown etiology, characterized by a broad spectrum of clinical manifestations. There is a large…
Abstract Number: 2309 • 2013 ACR/ARHP Annual Meeting
Quantifying The Gap Between General Population Guidelines and Expert Opinion For Cardiovascular Risk Management In Rheumatic Disease Patients
Katherine P. Liao¹, Jonathan Brown², Jonathan S. Coblyn³, Paul Cohen², Jorge Plutzky² and Daniel H. Solomon⁴, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Cardiology, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA
Background/Purpose: Cardiovascular (CV) risk is higher among rheumatic disease patients than the general population. However, CV risk management guidelines calibrated for the rheumatic disease population…
Abstract Number: 2131 • 2013 ACR/ARHP Annual Meeting
Osteoarthritis Pain: Variability and Clinical Correlations
Thomas J. Schnitzer¹, Renita Yeasted², Leijan Huang³, Jennifer Duffecy⁴, Mark Begale⁴ and A. Vania Apkarian³, ¹PM&R and Int Med, Northwestern University, Chicago, IL, ²PM&R, Northwestern University, Chicago, IL, ³Physiology, Northwestern University, Chicago, IL, ⁴Preventive Medicine, Northwestern University, Chicago, IL
Background/Purpose: Although osteoarthritis (OA) is an intensely studied model of chronic pain, little is known about the temporal dynamics of OA pain intensity and how…
Abstract Number: 2062 • 2013 ACR/ARHP Annual Meeting
Clinical Features and Outcome In Polymyositis Vs. Dermatomyositis Patients With The Anti-Jo-1 Autoantibody
Rohit Aggarwal¹, Diane Koontz², Zengbiao Qi³ and Chester V. Oddis⁴, ¹Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Department of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The clinical characteristics of dermatomyositis (DM) patients possessing the anti-Jo-1 autoantibody (autoAb) are not well known. We analyzed the clinical features and prognosis of…
Abstract Number: 1796 • 2013 ACR/ARHP Annual Meeting
12-Week Results Of a Phase 2b Dose-Ranging Study Of Baricitinib, An Oral JAK1/ JAK2 Inhibitor In Japanese Patients With Rheumatoid Arthritis On Background Methotrexate Therapy
Yoshiya Tanaka¹, Kahaku Emoto², Mika Tsujimoto², Douglas E. Schlichting³ and William Macias³, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Eli Lilly Japan K.K., Kobe, Japan, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (formerly LY3009104/INCB028050), a novel, oral inhibitor of JAK1 and JAK2 in the JAK-STAT signaling pathway, has been evaluated in a 12-week blinded phase…
Abstract Number: 1336 • 2013 ACR/ARHP Annual Meeting
The Safety and Feasibility Of a Treat-To-Target Strategy Aimed At Achieving a Simplified Disease Activity Index Of ¡Ü3.3 While Administering Entecavir In Rheumatoid Arthritis Complicated By Hepatitis B Virus
Yukitomo Urata¹, Yoshihide Nakamura^2,3 and Ken-ichi Furukawa⁴, ¹Seihoku Central Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan, ²Hirosaki University Graduate School of Medicine, Hirosaki, Japan, ³Orthopaedic Surgery, Seihoku Central Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan, ⁴Pharmacology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
Background/Purpose: To elucidate the safety and feasibility of a treat-to-target (T2T) strategy aimed at achieving a simplified disease activity index (SDAI) of ≤3.3 while administering…
Abstract Number: 1305 • 2013 ACR/ARHP Annual Meeting
Clinical Joint Involvement Is Decisive For Radiographic Progression
Miriam Gärtner¹, Farideh Alasti², Gabriela Supp¹, Josef S. Smolen³ and Daniel Aletaha¹, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Today’s therapeutic targets in rheumatoid arthritis (RA) are remission or low disease activity, but it was shown that joint damage may continue to progress…
Abstract Number: 33 • 2013 ACR/ARHP Annual Meeting
B Cell Receptor Signaling As A Potential Clinical Parameter In Lupus
Michael Faludi¹, Christian A. Pineau², Evelyne Vinet¹, Ann E. Clarke³, Sasha Bernatsky⁴, Joyce Rauch² and Emil P. Nashi⁵, ¹McGill University Health Center, Montreal, QC, Canada, ²Rheumatology, McGill University Health Center, Montreal, QC, Canada, ³Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ⁴Division of Clinical Epidemiology, McGill University Health Center, Montreal, QC, Canada, ⁵Immunology and Rheumatology, McGill University Health Center, Montreal, QC, Canada
Background/Purpose: B cells are central to SLE. Signaling through the B cell receptor (BCR) controls critical processes at various stages of B cell development. Murine…
Abstract Number: 116 • 2012 ACR/ARHP Annual Meeting
Correlation Between Clinical and Ultrasonographic Examination of the Calcaneal Enthesis in Patients with Ankylosing Spondylitis: A Controlled Study
Suellen Narimatsu¹, Rita N.V. Furtado¹, Andre Rosenfeld², Germana. B. Q. Estrela¹, Jorge E. P. Proglhof² and Jamil Natour³, ¹Rheumatology, Universidade Federal de São Paulo, São Paulo, Brazil, ²Radiology, Universidade Federal de São Paulo, São Paulo, Brazil, ³Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: 1 – To compare US findings of calcaneal entheses between AS patients and healthy subjects; 2 - To assess the calcaneal entheses by US…
Abstract Number: L8 • 2012 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Parallel-Group Study of the Safety and Efficacy of Tocilizumab Subcutaneous Versus Placebo in Combination with Traditional Dmards in Patients with Moderate to Severe Rheumatoid Arthritis (BREVACTA)
Alan J. Kivitz¹, Ewa Olech², Michael A. Borofsky³, Beatriz M. Zazueta⁴, Federico Navarro-Sarabia⁵, Lucy Rowell⁶, Clare Nasmyth-Miller⁶ and Janet E. Pope⁷, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Internal Medicine, University of Nevada School of Medicine, Las Vegas, NV, ³Clinical Research Center of Reading, Reading, PA, ⁴Reumatologia, Centro de Investigacion en Enfermedades Reumaticas, Mexicali, Mexico, ⁵Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain, ⁶Roche, Welwyn Garden City, United Kingdom, ⁷Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada
Background/Purpose: The intravenous formulation of tocilizumab (TCZ) has demonstrated efficacy with a manageable safety profile in patients (pts) with rheumatoid arthritis (RA) in multiple clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].